EFS in patients with the respective cytogenetically defined risk group separated according to day 16 blasts fewer than 10% versus 10% or more.

I indicates favorable cytogenetics and day 16 blasts fewer than 10% (n = 39, censored = 18; median, 25 months); II, favorable cytogenetics and day 16 blasts 10% or more (n = 6, censored = 5; median, not reached); III, prognostically intermediate cytogenetics and day 16 blasts fewer than 10% (n = 136, censored = 56; median, 14 months); IV, prognostically intermediate cytogenetics and day 16 blasts 10% or more (n = 81, censored = 24; median, 5 months); V, unfavorable cytogenetics and day 16 blasts fewer than 10% (n = 30, censored = 1; median, 6 months); VI, unfavorable cytogenetics and day 16 blasts 10% or more (n = 29, censored = 3; median, 2 months). The level of significance of the respective differences according to fewer than 10% versus 10% or more day 16 blasts within the groups with favorable, prognostically intermediate, and unfavorable cytogenetics are nonsignificant (ns),P = .00031 and P = .00768, respectively.